Form 4: Instil Bio CEO Bronson Crouch Reports Stock Option Grant

CEO Bronson Crouch of Instil Bio, Inc. reports the acquisition of stock options.

Summary

• On April 25, 2025, Bronson Crouch, CEO and Chairman of Instil Bio, Inc., reported the acquisition of 105,157 employee stock options.
• The exercise price of the options is $12.78.
• The options vest over time, with 25% vesting on April 25, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• The options expire on April 24, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning the CEO's interests with the company's long-term success.
• Employees may see this as a standard part of executive compensation.

Key Dates

Keywords

stock options, Form 4, Instil Bio, Bronson Crouch, CEO, beneficial ownership, securities